Experimental CAR-T therapy targets tough blood cancers
NCT ID NCT06208735
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a protein called CD22 on cancer cells, and infusing them back. The main goal is to find a safe dose and monitor side effects, with a secondary look at whether the treatment shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alberta Children's Hospital
RECRUITINGCalgary, Alberta, T3B 6A8, Canada
Contact Email: •••••@•••••
Contact
-
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
Contact Email: •••••@•••••
Contact
-
BC Children's Hospital
RECRUITINGVancouver, British Columbia, Canada
Contact
Contact Email: •••••@•••••
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, Canada
Contact Email: •••••@•••••
Contact
-
The Hospital for Sick Children
RECRUITINGToronto, Ontario, Canada
Contact Email: •••••@•••••
Contact
-
The Ottawa Hospital - General Campus
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
Contact
Contact
Contact Email: •••••@•••••
-
Vancouver General Hospital
RECRUITINGVancouver, British Columbia, V5Z 1M9, Canada
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CLIC-2201 (a type of CAR-T cell therapy that targets CD22 on cancer cells)
What this could lead to
If this works, it could offer a new treatment option for people with B-cell cancers that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 24 participants, so it is primarily checking safety. The therapy may not work or could cause serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.